UNSPSC 51285318: Nifurvidine

This classification denotes an anti-infective agent with the molecular formula C11H9N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y0G95D5K2W, chemically known as 4-pyrimidinol, 2-methyl-6-(2-(5-nitro-2-furyl)vinyl)- but more generally known as nifurvidine, which bears US NIH Compound Identifier 6441378. European Medicines Agency schedules Nifurvidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09282MIG. The term NIFURVIDINE is an International Non-Proprietary Name.

UNSPSC 51285318 Nifurvidine is a Commodity code for a specific pharmaceutical active ingredient, though recent state and local opportunities tagged under it show minimal direct alignment with nifurvidine procurement itself. The code sees sporadic activity from health departments and county governments acquiring pharmaceutical products through piggyback contracts and competitive bids, typically bundled with other medications or medical countermeasures as part of broader public health supply chains. State and local buyers use this classification when sourcing pharmaceuticals through cooperative purchasing vehicles and fixed-term supply agreements, often with renewal options spanning two to three years.

Recent opportunities show activity in Illinois and Florida. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026 (Bid 26-482DPH-PREPD-B-53392), supplying Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets over a 12-month initial term with two renewal options; Seminole County, Florida issued an IFB (IFB60459723LAS) with a July 26, 2023 response deadline for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, a two-year initial term plus one-year renewal option, and fixed-fee pricing on an electronic bid submission process. Neither opportunity directly involves nifurvidine, and the code shows little relevant recent activity in state and local procurement at present.